Zemits EvoPlasm

The Zemits EvoPlasm is a cold plasma system used to enhance aesthetic treatments - it clears, brightens and rejuvenates both skin and scalp. It is positioned as an add-on that lifts the result of any existing treatment rather than a stand-alone lifting modality: it is painless, has no downtime and requires no consumables, which makes it one of the cheapest devices in the category to run. **Key points:** - Modality: cold plasma (also marketed as high-frequency plasma energy in this category). - Treated areas: skin and scalp - so it supports facial protocols and scalp/hair-wellness services. - Controls: four intensity levels plus constant and pulse modes, giving clinicians a treatable range from sensitive facial work to scalp conditions. - Zero consumables: no tips, cartridges or gels are required to operate it. - No downtime reported in the listing, so it can be layered into an existing facial without changing the client's schedule. **Business case:** Consumable-free, zero-downtime devices are the easiest upsell in a facial menu - adding a plasma pass to an existing treatment costs no stock and only a few minutes of room time, so the incremental revenue carries almost no marginal cost. **Confidence:** High - modality, treatment areas, control modes, no-consumable design and no-downtime positioning are all stated in the product record. **Evidence source:** Product listing `zemits-evoplasm` (id=1121), fields: lede, what_it_is, how_it_works, who_for.

The regulatory status of the Zemits EvoPlasm cannot be confirmed from the current product data. The structured fields `fda_key`, `fda_label` and `fda_tone` are empty on the product record, and the listing text contains no FDA clearance, CE marking or equivalent certification claim. No conclusion about either clearance or non-clearance can be drawn from this data. **Key points:** - `fda_key`, `fda_label` and `fda_tone` are all empty. - No regulatory statement appears in the lede, what_it_is, how_it_works or who_for fields. - Cold plasma / high-frequency aesthetic devices are generally regulated as Class II devices in the US, reaching market via 510(k) premarket notification - so 'cleared' rather than 'approved' would be the correct term if a claim is made. - The listing's safety statements ('painless', 'no downtime', 'safe for every skin type') are marketing claims, not regulatory evidence. **⚠️ FLAG - procurement verification required.** Before purchase, obtain from the supplier: (1) the 510(k) number and cleared indication wording if a US claim is made, (2) CE marking documentation to EU MDR 2017/745 or UKCA evidence, (3) a signed regulatory status letter on company letterhead covering the exact model, (4) IEC 60601-1 electrical safety certification and the manufacturer's contraindication list for plasma treatment. **Business case:** Plasma devices are frequently resold across borders, so the clearance that applies to one market may not apply to yours - the regulatory status letter is the document that keeps a clinic compliant in its own jurisdiction. **Confidence:** Low - no FDA or equivalent regulatory information of any kind is present in the product data, so no status can be stated either way. **Evidence source:** Product listing `zemits-evoplasm` (id=1121), fields: fda_key, fda_label, fda_tone, lede, what_it_is, how_it_works, who_for (all regulatory fields empty).

The listing documents the device's controls - four intensity levels plus constant and pulse modes, no downtime - but does not publish a session schedule. Use the standard cold plasma protocol for this device class and confirm exact parameters with the manufacturer: a course of 4-6 sessions spaced 1-2 weeks apart for skin clearing and brightening, then maintenance every 4-6 weeks; single plasma passes can also be added to any existing facial. **Key points:** - Course: 4-6 sessions at 1-2 week intervals for cumulative brightening and skin clearing. - Control choice: pulse mode for sensitive or reactive skin, constant mode for scalp and resilient areas - select intensity from the four available levels and increase only on client tolerance. - Downtime: none reported in the listing, so sessions can be booked back-to-back with other facial treatments on the same day. - Maintenance: one session every 4-6 weeks keeps results and drives rebooking frequency. - Post-treatment: SPF and barrier support; avoid actives for 24 hours. **Business case:** No downtime plus a short treatment time means plasma is a high-frequency, low-cost add-on - it is best priced as an upsell attached to another service rather than as a stand-alone treatment, which increases revenue per visit without lengthening the appointment. **Confidence:** Medium - the device controls and no-downtime positioning are product-documented; the session count and intervals are standard clinical practice for cold plasma rather than published device specifications. **Evidence source:** Product listing `zemits-evoplasm` (id=1121), fields: lede, what_it_is, how_it_works, who_for.

Yes as far as the listing states - the Zemits EvoPlasm record describes the device as suitable for aesthetic practitioners and skin or scalp professionals 'who want to enhance results across all skin types'. That is an all-skin-types positioning, but it is a marketing statement in the `who_for` field, not a regulatory clearance or an independently verified clinical claim. **Key points:** - Stated positioning: results across all skin types (source: `who_for` field), so no Fitzpatrick exclusion is published for this plasma device. - Plasma treatment does not deposit heat the way HIFU or RF does, which is consistent with the listing's all-skin-types and no-downtime claims - but the listing provides no clinical data or clearance document to support them. - For Fitzpatrick IV-VI clients, still apply standard practice: start at the lowest of the four intensity levels in pulse mode and assess response before increasing. - Screen for: pregnancy, active infection or open lesions in the treatment area, implanted electronic devices (pacemakers, ICDs), metal implants in the treatment path and recent cosmetic procedures in the area. - Do not treat over the thyroid, eyes or mucous membranes, and use eye protection when working near the orbital area. **Business case:** An all-skin-types device materially widens the addressable client base for a facial menu - it lets a clinic advertise plasma add-ons without carving out a skin-type exclusion, which matters in markets with large Fitzpatrick IV-VI client populations. **Confidence:** Medium - the all-skin-types statement is explicitly present in the product record; it is a manufacturer marketing claim without supporting regulatory or clinical documentation in the data. **Evidence source:** Product listing `zemits-evoplasm` (id=1121), fields: lede, what_it_is, how_it_works, who_for ('safe for every skin type' in the lede; 'want to enhance results across all skin types' in who_for).